PME has fallen 28.3% making it the worst performing stock on the ASX200 so far this year with the trouble all around valuation as opposed to business quality. While P/E’s are fairly irrelevant for these sorts of stocks, 110x 2022 earnings is a number to keep in one’s mind but probably more telling is their price to sales multiple P/S which sits 69x. We like the growth available in the medical imaging IT provider which focuses on the radiology space, the debt free company boasts excellent profit margins with the hardest issue being what represents good value even after its corrected over 40%, we feel slow accumulation into current weakness will pay dividends in the years ahead.
scroll
Question asked
Question asked
Pulse Check Webinar: Navigating Trade Wars, AI and Trump’s market impact
Close
Monday 17th February – ASX -62pts BEN, WBC, BSL
Close
Video Update – January 2025 Portfolio Performance & Positioning
Close
Monday 17th Feb – Dow -165pts, SPI down -52pts
Close
MM is neutral / positive PME
Add To Hit List
Related Q&A
PME results / portfolio weightings
Does MM like Pro Medicus (PME) at current levels?
Relevant suggested news and content from the site

Video
WATCH
Pulse Check Webinar: Navigating Trade Wars, AI and Trump’s market impact
Recorded Thursday 6th February

Podcast
LISTEN
Monday 17th February – ASX -62pts BEN, WBC, BSL
Daily Podcast Direct from the Desk

Video
WATCH
Video Update – January 2025 Portfolio Performance & Positioning
Recorded Wednesday 15th January

Podcast
LISTEN
Monday 17th Feb – Dow -165pts, SPI down -52pts
Daily Podcast Direct from the Desk
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.